CG ONCOLOGY INC CGON
ASignal's systematic analysis rates CGON as Bearish.
Reflects the latest available analysis · analyzed Nov 15, 2026
The case on CGON
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong cash position with $984.46M in cash and minimal debt (debt/equity = 0.01x)
- High liquidity with current ratio of 21.70x indicating strong short-term financial health
- Positive MACD momentum (MACD > signal line) and rising histogram suggest strengthening uptrend
- Price above 20-day and 50-day moving averages, indicating bullish trend alignment
- Extremely high valuation metrics: price-to-sales at 1077.74x and EV/revenue at 919.58x
- Negative operating margin (-4293.53%) and negative ROE (-28.29%) indicating severe profitability issues
- Negative free cash flow ($-119.27M) and declining revenue (YoY growth: -3.7%)
- Overbought RSI at 67.46, approaching threshold of 70
- Lack of Reddit sentiment data and low news coverage (only 2 sources)
See the full verdict on CGON
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes CGON
Most investors never get a second opinion, let alone several. ASignal runs CGON past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.